Lv64
2530 积分 2023-11-20 加入
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
3个月前
已完结
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
3个月前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
3个月前
已完结
The global burden of lung cancer: current status and future trends
3个月前
已完结
Trastuzumab deruxtecan shows durable activity in HER2‐mutant non–small cell lung cancer
4个月前
已完结
Optimizing Dosing of Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer: A Reminder That More Is Not Always Better
4个月前
已完结
Speeding up Antibody-Drug Conjugate Development in Pretreated EGFR-Mutant Non–Small-Cell Lung Cancer
4个月前
已完结
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
6个月前
已完结
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial
6个月前
已完结
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
6个月前
已完结
皖公网安备34019202002308
